Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Rhea-AI Summary

Hemostemix (OTCQB: HMTXF) will attend DFCon 2025 in San Antonio to present clinical outcomes for ACP-01 (VesCell™) and meet clinicians and researchers over three days.

Phase II midpoint results as published by the University of Toronto: 0% mortality and 83% limb preservation at a 4.5-year midpoint for treated subjects; in a subgroup with ulcers (21 treated, 8 placebo) mean ulcer size fell from 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months; no treatment-related complications at one year.

Financing: TSXV approved a non-brokered private placement of $518,440 adding 520,090 units to a previously closed 4,193,000 units; each unit priced at $0.11 and includes one common share plus one warrant exercisable at $0.15 for two years, with an acceleration feature triggered if the 10-day VWAP exceeds $0.185.

Positive

• Phase II midpoint: 83% limb preservation at 4.5 years
• Ulcer reduction from 146 mm2 to 0.48 mm2 by 3 months (p = 0.01)
• Raised $518,440 via TSXV-approved non-brokered private placement

Negative

• Added 520,090 units with warrants that may dilute shareholders if exercised
• Warrants exercisable at $0.15 create near-term overhang until expiry or acceleration

News Market Reaction

-3.23%

1 alert

-3.23% News Effect

On the day this news was published, HMTXF declined 3.23%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Limb preservation: 83% of subjects Mortality rate: 0% Ulcer size reduction: 146 mm2 to 0.48 mm2 +5 more

8 metrics

Limb preservation 83% of subjects Phase II midpoint limb preservation over 4.5 years

Mortality rate 0% Phase II treated cohort vs 50% for no-option patients over 5 years

Ulcer size reduction 146 mm2 to 0.48 mm2 Treated group by 3 months, p = 0.01

Treatment sample sizes 21 treated, 8 placebo Subgroup presenting with wound ulcers

Amputation rates 4.8% vs 25% Treatment vs placebo group in study

Private placement size $518,440 TSXV-approved non-brokered private placement

Units issued 520,090 Units Additional Units added to 4,193,000 previously closed

Unit and warrant prices $0.11 / $0.15 Unit price and warrant exercise price, 2-year term

Market Reality Check

Price: $0.0686 Vol: Volume 22000 is 1.53x the...

high vol

$0.0686 Last Close

Volume Volume 22000 is 1.53x the 20-day average of 14402 ahead of/around this news. high

Technical Shares at 0.06364 are trading below the 200-day MA of 0.09, indicating a weak longer-term trend.

Peers on Argus

Peers showed mixed moves, from +2400% in RDTCF and +15.96% in MRES to a -7.63% d...

Peers showed mixed moves, from +2400% in RDTCF and +15.96% in MRES to a -7.63% decline in TELIF, while others were flat. With no momentum flags or news in direct peers, HMTXF’s reaction appeared stock-specific rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	Regulatory & financing	Positive	+0.9%	FDA Pre-IND meeting scheduled and new non-brokered private placement proposed.
Dec 03	Conference presentation	Positive	-8.9%	Conference feature with strong ACP-01/VesCell limb salvage and ulcer reduction data.
Dec 02	Conference & financing	Neutral	-3.2%	DFCon attendance highlighting Phase II data plus TSXV-approved private placement closing.
Nov 26	Acquisitions & financing	Positive	-3.2%	Binding LOI to acquire two cardiology practices and financing extension approval.
Nov 18	Conference & data	Positive	+6.6%	Showcasing Phase II wound-healing results and broader ACP-01 experience plus market sizing.

Pattern Detected

Recent news produced mixed reactions: several clinically or strategically positive updates aligned with price gains, but conference and acquisition/financing headlines sometimes saw selling, suggesting inconsistent follow-through on good news.

Recent Company History

Over late 2025, Hemostemix issued a series of updates spanning clinical visibility, practice roll-ups, and financings. On Nov 18 and Dec 3, the company highlighted ACP-01/VesCell data and conference presentations, including ulcer size reductions from 146 mm2 to 0.48 mm2 and favorable amputation and mortality rates. It also pursued a cardiology practice roll-up strategy and multiple non-brokered financings, including Units at $0.11 with $0.15 warrants. This DFCon/private placement release fits the pattern of combining scientific exposure with ongoing capital raises.

Market Pulse Summary

This announcement combines notable clinical validation for ACP-01/VesCell with the closing of a non-...

Analysis

This announcement combines notable clinical validation for ACP-01/VesCell with the closing of a non-brokered private placement. Phase II data highlighted 0% mortality, 83% limb preservation, and ulcer size reductions from 146 mm2 to 0.48 mm2, supporting the treatment’s efficacy profile. The $518,440 financing at $0.11 per Unit with $0.15 warrants adds capital but also dilution. Investors may monitor future trial progress, regulatory milestones, and additional financings as key drivers of the story.

Key Terms

phase II clinical trial, placebo, p = 0.01, non brokered private placement, +4 more

8 terms

phase II clinical trial medical

"midpoint result in our phase II clinical trial! Unblinded the 83%"

A Phase II clinical trial is a mid-stage study in humans that tests whether an experimental drug or treatment actually works and what dose is effective, typically involving dozens to a few hundred patients and often comparing outcomes to a placebo or standard care. For investors, Phase II results are a major inflection point: clear positive data can substantially increase the odds of later regulatory approval and company value, while negative or uncertain results raise development risk and can sharply reduce expectations—like a detailed test drive after basic safety checks.

placebo medical

"patients who presented with wound ulcers before administration of ACP-01, (21 treatment, 8 placebo),"

A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.

p = 0.01 medical

"Ulcer size in the treated group decreased from a mean of 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months"

p = 0.01 means there is a 1% probability of observing the study or test result if, in reality, there were no real effect or difference. For investors, that low probability signals stronger statistical evidence that an observed effect is unlikely to be due to random chance—like seeing one head in 100 coin flips when expecting a fair coin—but it is not proof of practical importance or a guarantee of future outcomes.

non brokered private placement financial

"The TSXV has approved a non brokered private placement of $518,440, adding 520,090 units"

A non-brokered private placement is a direct sale of a company’s securities, such as shares or bonds, to a limited group of investors without using an outside broker or dealer. It matters to investors because it can raise capital quickly with lower fees and less public disclosure, but may dilute existing ownership and provide fewer market checks on price — like borrowing from close contacts instead of taking a loan through a public bank.

warrant financial

"one common share purchase warrant (a "Warrant"). Each full Warrant entitles the holder"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

weighted average price financial

"greater than a weighted average price of $0.185 per Common Share, the Company may"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tsx venture exchange regulatory

"closing sales price of the Common Shares ... as quoted on the TSX Venture Exchange"

A junior stock exchange in Canada where smaller, early-stage companies list shares to raise capital and gain public visibility. Think of it as a farmers’ market for young businesses: it offers investors a chance to buy into fast-growing but higher-risk ventures, with looser listing rules and typically lower liquidity than major exchanges. It matters because performance and financing on this exchange can signal growth prospects or risk for investors.

expiry date technical

"press release that the expiry date of the Warrants will be accelerated to the date"

The expiry date is the final day a financial contract such as an option or futures contract is valid; after that date the contract either must be exercised, settled, or it becomes worthless. Investors care because the approaching expiry changes a contract’s value and risk—time left determines how much price movement is needed to profit, affects strategy choices, and can trigger automatic settlement like a used coupon or an expired ticket.

AI-generated analysis. Not financial advice.

Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeons, wound-care experts, infectious disease specialists, endocrinologists/diabetologists, cardiovascular and endovascular specialists, nurses, NPs, PAs, residents, fellows, physical therapists, and industry innovators.

"VesCell saves diabetic limbs from amputation, and that saves lives," stated Thomas Smeenk CEO. DFCon remains the world's leading interdisciplinary diabetic foot conference, and we are delighted to be a solution-based participant. Here is why: as compared to a 50% mortality rate within five years for no option patients, the University of Toronto published our treatment generated 0% mortality and limb preservation in 83% of subjects followed for 4.5 years as a midpoint result in our phase II clinical trial! Unblinded the 83% received VesCell. As published, looking at only the patients who presented with wound ulcers before administration of ACP-01, (21 treatment, 8 placebo), Ulcer size in the treated group decreased from a mean of 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months (wounds decreased from the size of a wild strawberry to the size of a grain of sand). There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment. The treatment group had one amputation (4.8%) and one death (4.8%); the placebo group had 2 amputations (25%) and 1 death (12.5%)," and that story needs to be told," Smeenk said.

Across three high-intensity days - Friday, Saturday, and Sunday - Hemostemix will meet with clinicians, researchers, and innovators to highlight the significant outcomes following treatment with ACP-01 (VesCell™), for vascular and ischemic conditions that underpin chronic wounds and diabetic limb-threatening ischemia.

Financing

The TSXV has approved a non brokered private placement of $518,440, adding 520,090 units ("Units") to the previously announced closing of 4,193,000 units ("Units"), each at a price of $0.11 per Unit. Each Unit consists of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"). Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.15 per share for a period of two (2) years from the closing date of the Offering, subject to the accelerated expiry provision described as follows. If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange (the "Exchange") is greater than a weighted average price of $0.185 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the date that is 30 days following such press release.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Phase I clinical trial of ACP-01 as a treatment for Vascular Dementia, and the treatment of pain related to CLTI in Florida and other jurisdictions related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276563

FAQ

What Phase II results did Hemostemix (HMTXF) report for ACP-01 (VesCell) on December 2, 2025?

University of Toronto midterm Phase II results reported 0% mortality and 83% limb preservation at 4.5 years; ulcer size fell from 146 mm2 to 0.48 mm2 by 3 months (p = 0.01).

How much did Hemostemix (HMTXF) raise in the December 2025 private placement and how many units were issued?

The TSXV approved a non-brokered private placement of $518,440, issuing 520,090 units in addition to a previously closed 4,193,000 units.

What are the warrant terms from Hemostemix's (HMTXF) private placement closed December 2, 2025?

Each unit includes a warrant exercisable for one common share at $0.15 for two years, with an acceleration provision if the 10-day weighted average exceeds $0.185.

What will Hemostemix (HMTXF) present at DFCon 2025 in San Antonio?

Hemostemix will highlight clinical outcomes for ACP-01 (VesCell) and meet clinicians, researchers, and industry partners across three days to discuss limb preservation data and applications.

Does the Hemostemix (HMTXF) announcement report any safety issues from the ACP-01 trial?

The announcement states there were no complications related to treatment at one year in the published Phase II results.